01961nas a2200193   4500008003900000245013200039210006900171260000800240300000700248490000700255520137600262100001301638700001201651700001601663700001501679700001401694700001401708856004501722       2019                          d00aEuropean experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation0 aEuropean experience and risk factor analysis of donor cellderive  cFeb  a080 v333 aDonor cell leukaemia (DCL) is a rare complication of allogeneic haematopoietic cell transplantation (HCT). We have investigated the prevalence and outcome of donor cell haematology malignancies within centres registered with the European Society of Blood and Marrow transplantation (EBMT). We have sought to identify risk factors to shed light on the pathogenesis of DCL as a model for leukaemogenesis. DCL cases were identified by questionnaire and a follow-up questionnaire requested detailed data. Control subjects from the EBMT registry who had not developed DCL were used for a matched pair analysis to identify risk factors. We identified 38 patients with DCL; the estimated prevalence was 80.5/100,000 transplants. Patients were predominantly treated for haematological malignancy. A clone was retrospectively identified in 7/25 (28%) donors for whom data was available. Overall survival was poor with 29/38 patients dead a median of 11 (range 0-91) months after DCL diagnosis. Matched case-pair analysis identified three factors on multivariate analysis as significantly associated with an increased risk for DCL: use of growth factors within the first 100 days after transplantation, in vivo T-cell depletion and multiple allografts. The risk factors identified, support reduced immune surveillance and replicative stress as pathogenic in the development of DCL.1 aEngel, N1 aRovo, A1 aBadoglio, M1 aLabopin, M1 aBasak, GW1 aBeguin, Y  uhttp://613633.bywedr.asia/reference/4883